TNF and inflammatory bowel disease: A large retrospective analysis of a US claims database reported no significant link between TNFα inhibitor therapy and NMSC in IBD patients (OR: 1.14; 95% CI: 0.95–1.36), with similar results observed when analyses were limited to patients with CD (OR: 1.16; 95% CI: 0.95–1.41) or UC (OR: 1.06; 95% CI: 0.69–1.64) [15].